148 related articles for article (PubMed ID: 1665138)
1. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer].
Schelling M; Jänicke F; Senekowitsch R; Lörken A
Gynakol Rundsch; 1991; 31 Suppl 2():286-9. PubMed ID: 1665138
[No Abstract] [Full Text] [Related]
2. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Pellagatta L; Bianchi R; Fioretti P
J Nucl Biol Med (1991); 1991; 35(1):33-7. PubMed ID: 1657201
[TBL] [Abstract][Full Text] [Related]
3. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
4. Tumor associated trypsin inhibitor and CA-125 during treatment of mucinous ovarian cancer in 2 patients.
Mogensen O
Eur J Cancer; 1991; 27(9):1180-1. PubMed ID: 1659852
[No Abstract] [Full Text] [Related]
5. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
[No Abstract] [Full Text] [Related]
6. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
Suzuki M; Sekiguchi I; Tamada T
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
8. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
[TBL] [Abstract][Full Text] [Related]
9. [High CA-125 values in a patient with miliary tuberculosis and ascites].
Klein M; Marczewski A; Rosen A; Beck A
Gynakol Rundsch; 1989; 29 Suppl 2():355-6. PubMed ID: 2613049
[No Abstract] [Full Text] [Related]
10. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
Nagele F; Vavra N; Kurz C; Sevelda P
Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
13. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
14. [New technology of diagnosis of ovarian cancer].
Terashima Y
Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169
[TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
[TBL] [Abstract][Full Text] [Related]
16. Total inhibin is a potential serum marker for epithelial ovarian cancer.
Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F
J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066
[TBL] [Abstract][Full Text] [Related]
17. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
18. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
[TBL] [Abstract][Full Text] [Related]
19. [Comments on the paper by Schröck et al., The simultaneous determination of Ca 125 and D-dimer in plasma and ascitic fluid in ovarian cancer].
Mezger J
Onkologie; 1986 Feb; 9(1):10. PubMed ID: 3523340
[No Abstract] [Full Text] [Related]
20. [Detection of CA 125 in the serum and tissue of patients with ovarian neoplasms].
Kristen P; Beier HJ; Kaesemann H; Caffier H
Gynakol Rundsch; 1989; 29 Suppl 2():358-60. PubMed ID: 2693257
[No Abstract] [Full Text] [Related]
[Next] [New Search]